(Q28253122)

English

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

scientific article

In more languages

Statements

scholarly article

0 references

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial (English)

0 references

0 references

multicenter clinical trial

0 references

steatohepatitis

0 references

liver cirrhosis

0 references

obeticholic acid

1 reference

ChEBI release 2020-05-28

placebo-controlled trial

1 reference

based on heuristic

inferred from title

non-alcoholic steatohepatitis

1 reference

based on heuristic

inferred from title

David E. Kleiner

17

object named as

David E Kleiner

0 references

Elizabeth M. Brunt

16

object named as

Elizabeth M Brunt

0 references

Kris V. Kowdley

11

object named as

Kris V Kowdley

0 references

4

object named as

Joel E Lavine

0 references

Jeanne M. Clark

object named as

Jeanne M Clark

14

1 reference

ORCID Public Data File 2021

Norah A Terrault

13

object named as

Norah Terrault

0 references

5

object named as

Mark L Van Natta

0 references

author name string

Brent A Neuschwander-Tetri

1

0 references

Rohit Loomba

2

0 references

Arun J Sanyal

3

0 references

Manal F Abdelmalek

6

0 references

Naga Chalasani

7

0 references

Srinivasan Dasarathy

8

0 references

Anna Mae Diehl

9

0 references

Bilal Hameed

10

0 references

Arthur McCullough

12

0 references

James Tonascia

15

0 references

Edward Doo

18

0 references

language of work or name

0 references

publication date

14 March 2015

0 references

0 references

385

0 references

9972

0 references

956-65

0 references

Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

20 March 2017

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

20 March 2017

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

7 April 2017

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

7 April 2017

Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

29 September 2017

Pharmacological agents for NASH.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

29 September 2017

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

29 September 2017

The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

29 September 2017

Pleiotropic roles of bile acids in metabolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

29 September 2017

Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

29 September 2017

Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

29 September 2017

Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

29 September 2017

Deciphering the nuclear bile acid receptor FXR paradigm

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

29 September 2017

Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

29 September 2017

A role of the bile salt receptor FXR in atherosclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

29 September 2017

Bile acids as regulators of hepatic lipid and glucose metabolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

29 September 2017

Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

29 September 2017

FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

29 September 2017

Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

29 September 2017

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

29 September 2017

Liver transplantation for nonalcoholic steatohepatitis: the new epidemic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

2 June 2018

Do therapeutic bile acids hit the sweet spot of glucose metabolism in NAFLD?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

27 November 2018

Population-based risk factors and resource utilization for HCC: US perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

27 November 2018

The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447192

27 November 2018

Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961933-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961933-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Computations for group sequential boundaries using the Lan-DeMets spending function method

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961933-4

7 January 2021

based on heuristic

inferred from DOI database lookup

NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/25468160

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28253122&oldid=2013953165"